Several genotype clusters were observed to be associated Azole antifungal agents have added greatly to the therapeutic options for treatment of systemic fungal infections
A multicenter, randomized pilot study by the NIAID-MSG demonstrated that fluconazole (200 and 400 mg/day) was moderately effective in the treatment of patients with non-life
The antifungal effects of the azoles are targeted primarily at ergosterol, Azoles first became available in 1973 with the arrival of clotrimazole; with additional azoles that have the pharmaceutical industry has rolled out over the past five decades: miconazole (1979)
Recent data also show that miconazole, the active ingredient in MONISTAT®, treats C
4% (744/823) being cross-resistant to voriconazole
Flucytosine and fluconazole display low protein binding and are eliminated by the kidney